Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

• Published in: The oncologist (Dayton, Ohio) Vol. 25; no. 5; pp. e808 - e815
• Main Authors: Kamath, Suneel D., Kalyan, Aparna, Kircher, Sheetal, Nimeiri, Halla, Fought, Angela J., Benson, Al, Mulcahy, Mary
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.05.2020
• Subjects: Gastrointestinal Cancer; Gemcitabine; Immune checkpoint inhibition; Immunotherapy; Ipilimumab; Pancreatic cancer; Immune checkpoint inhibition; Gemcitabine; Immunotherapy; Ipilimumab; Pancreatic cancer

Background Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemot...